Clinical Insights

Desiree Matthews, PMHNP-BC, offers a framework for choosing an initial antidepressant agent for major depressive disorder.

Psych Congress Steering Committee member Saundra Jain, MA, PsyD, LPC, discusses how clinicians can support patients through the early stages of treatment for major depressive disorder.

Erin Crown, MHS, PA-C, CAQ-Psychiatry, shares several communication strategies to effectively address patient concerns when considering augmentation for major depressive disorder (MDD).

Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN, explains key differences in stimulant and non-stimulant treatment options for ADHD.

Julie Carbray, PhD, PMHNP-BC, APRN, discusses how emerging therapies for bipolar disorder differ from traditional mood stabilizers, including improved tolerability and reduced side effects.

Julie Carbray, PhD, PMHNP-BC, APRN, provides an overview of some of the key cardiometabolic symptoms and adverse effects that clinicians should be on the lookout for in their patients with bipolar disorder.

Brittany Albright, MD, MPH, consultant, Psych Congress, and Kristian Dambrino, DNP, PMHNP-BC, consultant, Psych Congress, discuss common pitfalls when it comes to diagnosing MDD and TRD, as well as tools that clinicians have at their disposal...

Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC,, discuss referral practices for esketamine and transcranial magnetic stimulation for patients with depression.

Brittany Albright, MD, MPH, and Kristian Dambrino, DNP, PMHNP-BC, discuss the difference between major depressive disorder and treatment-resistant depression, plus monoaminergic versus glutamatergic treatments.

In this video, Hara Oyedeji, APRN, PMHNP-BC, MSEd, offers guidance to APPs navigating LAI initiation while considering oral overlap requirements in the treatment of schizophrenia.